{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:21Z","timestamp":1792831041375,"version":"4.5.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008253","name":"Shaoxing University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22278270"],"award-info":[{"award-number":["22278270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110641","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:09:55Z","timestamp":1791846595000},"page":"110641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploiting selective aldo-keto reductase 1C3 inhibitors and beyond: recent advances and future directions in cancer therapy"],"prefix":"10.1016","volume":"183","author":[{"given":"Guoqi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runpu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110641_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110641_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Weinberg, Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110641_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2026.110641_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.steroids.2013.10.012","article-title":"Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism","volume":"79","author":"Ri\u017ener","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.bioorg.2026.110641_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jsbmb.2009.12.009","article-title":"Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer","volume":"118","author":"Byrns","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0090","first-page":"995","article-title":"Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I\/II study, Invest. New","volume":"32","author":"Loriot","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110641_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40268-023-00427-5","article-title":"Hepatotoxicity of AKR1C3 inhibitor BAY1128688: findings from an early terminated phase IIa trial for the treatment of endometriosis","volume":"23","author":"Hilpert","year":"2023","journal-title":"Drugs. R. D."},{"key":"10.1016\/j.bioorg.2026.110641_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ejendo\/lvad063","article-title":"Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study","volume":"189","author":"Gashaw","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0105","article-title":"A phase I\/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)","volume":"42","author":"Ryan Leibrandt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0750","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.111.180703","article-title":"Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy","volume":"337","author":"Gu","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0755","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-024-01180-x","article-title":"The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia","volume":"14","author":"Toscan","year":"2024","journal-title":"Blood. Cancer. J."},{"key":"10.1016\/j.bioorg.2026.110641_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mce.2005.10.024","article-title":"Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues","volume":"248","author":"Sharma","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): Roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/13543776.2017.1379503","article-title":"Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review","volume":"27","author":"Penning","year":"2017","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110641_bb0045","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","volume":"75","author":"Byrns","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0050","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL","volume":"25","author":"Evans","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2014.04.027","article-title":"Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3","volume":"278","author":"Hofman","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): Overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110641_bb0065","first-page":"8","article-title":"AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma","volume":"12","author":"Cho","year":"2025","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsbmb.2010.11.004","article-title":"Inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights","volume":"125","author":"Byrns","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0075","article-title":"AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0080","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","article-title":"Overview of AKR1C3: Inhibitor Achievements and Disease Insights","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104446","article-title":"Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis","volume":"152","author":"Ri\u017ener","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0110","article-title":"Emerging small-molecule AKR1C3 inhibitors development for cancer therapy: Progress from 2021 to 2025","volume":"304","author":"Gao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0115","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2026.110641_bb0120","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1021\/bi036046x","article-title":"Crystal structure of human prostaglandin F synthase (AKR1C3)","volume":"43","author":"Komoto","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2026.110641_bb0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj3260625","article-title":"Comparative anatomy of the aldo-keto reductase superfamily","volume":"326","author":"Jez","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.110641_bb0130","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/0008-5472.CAN-03-2847","article-title":"Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin Free","volume":"64","author":"Lovering","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0135","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1021\/bi9723055","article-title":"Mutagenesis of 3 alpha-hydroxysteroid dehydrogenase reveals a \"push-pull\" mechanism for proton transfer in aldo-keto reductases","volume":"37","author":"Schlegel","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2026.110641_bb0140","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1021\/acs.jmedchem.4c03035","article-title":"Discovery of hipghly potent AKR1C3 inhibitors treating sorafenib-resistant hepatocellular carcinoma","volume":"68","author":"Xing","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0145","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1021\/bi051861t","article-title":"Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost","volume":"45","author":"Komoto","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2026.110641_bb0150","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1074\/jbc.M606784200","article-title":"Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids","volume":"282","author":"Qiu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0155","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2026.110641_bb0160","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0165","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2174\/156800911796798904","article-title":"Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer","volume":"11","author":"Shiota","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bioorg.2026.110641_bb0170","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2003.11.102","article-title":"Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663","volume":"21","author":"Taplin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/0008-5472.CAN-24-0591","article-title":"An autophagy-targeting chimera induces degradation of androgen receptor mutants and AR-v7 in castration-resistant prostate cancer","volume":"85","author":"Bae","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0185","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/ERC-18-0289","article-title":"Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond","volume":"26","author":"Linder","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0190","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","article-title":"AKR1C3 as a target in castrate resistant prostate cancer","volume":"137","author":"Adeniji","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0200","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/0008-5472.CAN-09-2092","article-title":"Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer","volume":"70","author":"Hofland","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2011.02.027","article-title":"PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3","volume":"306","author":"Downs","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0210","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/1471-2407-10-672","article-title":"Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression","volume":"10","author":"Dozmorov","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0215","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0220","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/2767-9764.CRC-23-0235","article-title":"AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3\u03b2,17\u03b2-Diol","volume":"3","author":"Detlefsen","year":"2023","journal-title":"Cancer. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.110641_bb0225","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jsbmb.2017.04.009","article-title":"17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation","volume":"171","author":"Xu","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2020.108638","article-title":"Type 5 17-hydroxysteroid dehydrogenase\/prostaglandin F synthase (AKR1C3) inhibition and potential anti-proliferative activity of cholest-4-ene-3,6-dione in MCF-7 breast cancer cells","volume":"159","author":"Sali","year":"2020","journal-title":"Steroids"},{"key":"10.1016\/j.bioorg.2026.110641_bb0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cbi.2008.10.024","article-title":"Type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase (AKR1C3): Role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs","volume":"178","author":"Byrns","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110641_bb0240","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.mce.2015.07.008","article-title":"11beta-Prostaglandin F2alpha, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer","volume":"413","author":"Yoda","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0245","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.mce.2008.08.026","article-title":"Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors","volume":"301","author":"Laplante","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.annonc.2024.10.824","article-title":"Estrogens and breast cancer","volume":"36","author":"Kim","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0255","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1530\/JOE-20-0106","article-title":"Androgens, oestrogens and endometrium: a fine balance between perfection and pathology","volume":"246","author":"Gibson","year":"2020","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0260","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.3390\/jcm9124105","article-title":"AKR1C3 Is associated with better survival of patients with endometrial carcinomas","volume":"9","author":"Hojnik","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2026.110641_bb0265","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2013.11.032","article-title":"Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix","volume":"132","author":"Wu","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0270","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.suc.2020.02.013","article-title":"Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma","volume":"100","author":"Mejia","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"10.1016\/j.bioorg.2026.110641_bb0275","first-page":"4515","article-title":"AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies","volume":"18","author":"Zhao","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0280","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-20-2480","article-title":"A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-\u03baB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0285","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mc.23527","article-title":"AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP\/SLC7A11 signaling pathway","volume":"62","author":"Chen","year":"2023","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2026.110641_bb0290","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41388-022-02379-7","article-title":"AKR1C3 regulated by NRF2\/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma","volume":"41","author":"Pan","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110641_bb0295","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2026.110641_bb0300","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.3390\/cancers12123731","article-title":"Bruton's tyrosine kinase inhibitors ibrutinib and acalabrutinib counteract anthracycline resistance in cancer cells expressing AKR1C3","volume":"12","author":"Morell","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110641_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100361","article-title":"Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers","volume":"14","author":"Murray","year":"2019","journal-title":"Contemp. Clin. Trials. Commun."},{"key":"10.1016\/j.bioorg.2026.110641_bb0310","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","article-title":"Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-Cell acute lymphoblastic leukemia","volume":"62","author":"Verma","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0315","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13402-020-00571-z","article-title":"AKR1C3 is a biomarker and druggable target for oropharyngeal tumors","volume":"44","author":"Peraldo-Neia","year":"2021","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.bioorg.2026.110641_bb0320","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/genes13060997","article-title":"Identification and validation of a prognostic signature for thyroid cancer based on ferroptosis-related genes","volume":"13","author":"Wang","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.bioorg.2026.110641_bb0325","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1139\/bcb-2015-0096","article-title":"Transcript level of AKR1C3 is down-regulated in gastric cancer","volume":"94","author":"Frycz","year":"2016","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0330","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cbin.11789","article-title":"ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3","volume":"46","author":"Li","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bioorg.2026.110641_bb0335","doi-asserted-by":"crossref","first-page":"48050","DOI":"10.18632\/oncotarget.10347","article-title":"Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110641_bb0340","article-title":"Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress","volume":"9","author":"Koritzinsky","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110641_bb0345","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.2147\/CMAR.S166942","article-title":"Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of AKR1C3","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0350","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/cgt.2013.15","article-title":"Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer","volume":"20","author":"Xie","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jb\/mvac098","article-title":"Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells","volume":"173","author":"Matsunaga","year":"2023","journal-title":"J. Biochem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0360","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1124\/pharmrev.120.000122","article-title":"Aldo-Keto Reductases and Cancer Drug Resistance","volume":"73","author":"Penning","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2026.110641_bb0365","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1074\/jbc.M006655200","article-title":"The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene","volume":"276","author":"Burczynski","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bcp.2018.08.001","article-title":"Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment","volume":"156","author":"Novotn\u00e1","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108839","article-title":"Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells","volume":"314","author":"Matsunaga","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110641_bb0380","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2014.12.022","article-title":"Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss","volume":"69","author":"Zhong","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110641_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0390","doi-asserted-by":"crossref","first-page":"12512","DOI":"10.3390\/ijms222212512","article-title":"Transcriptomic profiling reveals AKR1C1 and AKR1C3 mediate cisplatin resistance in signet ring cell gastric carcinoma via autophagic cell death","volume":"22","author":"Phoo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110641_bb0395","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3892\/or.2017.5480","article-title":"Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity","volume":"37","author":"Shiiba","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.110641_bb0400","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20111286","article-title":"Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily","volume":"440","author":"Ruiz","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.110641_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109295","article-title":"Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells","volume":"332","author":"Matsunaga","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110641_bb0410","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41416-018-0014-0","article-title":"AKR1C enzymes sustain therapy resistance in paediatric T-ALL","volume":"118","author":"Bortolozzi","year":"2018","journal-title":"Brit. J. Cancer."},{"key":"10.1016\/j.bioorg.2026.110641_bb0415","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1080\/10715762.2016.1236373","article-title":"Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance","volume":"50","author":"Matsunaga","year":"2016","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cbi.2019.02.012","article-title":"Protective effect of inducible aldo-keto reductases on 4-hydroxynonenal-induced hepatotoxicity","volume":"304","author":"Li","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110641_bb0425","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.110641_bb0430","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.7150\/ijms.9239","article-title":"AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells","volume":"11","author":"Zhao","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bioorg.2026.110641_bb0435","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3727\/096504016X14772315906527","article-title":"CLIC1 induces drug resistance in human choriocarcinoma through positive regulation of MRP1","volume":"25","author":"Wu","year":"2017","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0440","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0445","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.7150\/thno.74974","article-title":"AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110641_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110038","article-title":"AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p","volume":"84","author":"Pan","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2026.110641_bb0455","first-page":"211","article-title":"Androgen receptor signalling in prostate cancer: mechanisms of resistance to endocrine therapies","volume":"17","author":"Quistini","year":"2025","journal-title":"Res. Rep. Urol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0460","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","article-title":"Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies","volume":"99","author":"Saatci","year":"2021","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110641_bb0465","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2119\/molmed.2012.00296","article-title":"Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer","volume":"18","author":"Hamid","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110641_bb0470","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2018.10.019","article-title":"The role of 17\u03b2HSDs in breast tissue and breast cancers","volume":"489","author":"McNamara","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0475","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0480","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-20-0015","article-title":"Cross-resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 axis in advanced prostate cancer","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0485","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1186\/s12885-021-09040-8","article-title":"The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0490","first-page":"370","article-title":"Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases, Pharmacogenet","volume":"26","author":"Platt","year":"2016","journal-title":"Genomics"},{"key":"10.1016\/j.bioorg.2026.110641_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2022.106121","article-title":"Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase)","volume":"221","author":"Detlefsen","year":"2022","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0500","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41568-025-00864-1","article-title":"Decoding ferroptosis for cancer therapy","volume":"25","author":"Wahida","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0505","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/cas.70403","article-title":"AKR1C3 binds \u03b2-Trcp to promote the degradation of TFRC to protect hepatocellular carcinoma from ferroptosis","volume":"117","author":"Qi","year":"2026","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110641_bb0510","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41419-019-2143-7","article-title":"Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis","volume":"10","author":"Gagliardi","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110641_bb0515","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41419-025-07773-z","article-title":"AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5","volume":"16","author":"Ju","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110641_bb0545","first-page":"646","article-title":"Reversal of apalutamide and darolutamide aldo-keto deductase 1C3-mediated resistance by a small molecule inhibitor, ACS","volume":"15","author":"Morsy","year":"2020","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0560","first-page":"341","article-title":"X-ray structure of human aldo-keto reductase 1C3 in complex with a bile acid fused tetrazole inhibitor: experimental validation, molecular docking and structural analysis, RSC","volume":"14","author":"Marinovi\u0107","year":"2023","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115013","article-title":"Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer","volume":"247","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0625","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejmech.2013.01.047","article-title":"Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3","volume":"62","author":"Heinrich","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0630","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1021\/jm3007867","article-title":"3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-\u03b2-hydroxysteroid dehydrogenase AKR1C3","volume":"55","author":"Jamieson","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0670","first-page":"437","article-title":"Bioisosteres of indomethacin as inhibitors of aldo-keto reductase 1C3, ACS. Med","volume":"10","author":"Lolli","year":"2019","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0735","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/0008-5472.CAN-24-0440","article-title":"LX1 dual targets AR variants and AKR1C3 in advanced prostate cancer therapy","volume":"84","author":"Ning","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0775","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1021\/acs.jmedchem.5c03834","article-title":"Visualizable, AKR1C3-activated small-molecule antitumor drug conjugates with ultra-low systemic toxicity","volume":"69","author":"Kang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0520","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1248\/bpb.26.1057","article-title":"Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines","volume":"26","author":"Akao","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2026.110641_bb0525","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1021\/np201002x","article-title":"Selective inhibition of human type-5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis","volume":"75","author":"Endo","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2026.110641_bb0530","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1016\/j.bmc.2014.08.007","article-title":"Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3","volume":"22","author":"Endo","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0535","first-page":"774","article-title":"Selective AKR1C3 inhibitors potentiate chemotherapeutic activity in multiple acute myeloid leukemia (AML) cell lines, ACS. Med","volume":"7","author":"Verma","year":"2016","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0540","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-17-1023","article-title":"AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells","volume":"17","author":"Verma","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0550","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1021\/acs.jmedchem.3c00732","article-title":"Aldo-keto reductase 1C3 inhibitor prodrug improves pharmacokinetic profile and demonstrates in vivo efficacy in a prostate cancer xenograft model","volume":"66","author":"Maddeboina","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0555","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1039\/C8MD00077H","article-title":"Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity","volume":"9","author":"Savi\u0107","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.bioorg.2026.110641_bb0565","first-page":"232","article-title":"Synthesis and biological evaluation of novel D-ring fused steroidal N(2)-substituted-1,2,3-triazoles, RSC","volume":"16","author":"Tenjovi\u0107","year":"2025","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2025.106874","article-title":"Canine aldo-keto reductase 1C3 (AKR1C3\/PGFS) exhibits 17\u03b2\/20\u03b1-hydroxysteroid dehydrogenase activity and is inhibited by trilostane","volume":"255","author":"Endo","year":"2026","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0575","first-page":"1127","article-title":"Synthesis, in vitro and in silico anticancer evaluation of novel pyridin-2-yl estra-1,3,5(10)-triene derivatives, Future","volume":"16","author":"Stevanovi\u0107","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0580","series-title":"N-Benzoyl Anthranilic Acid Derivatives as Selective Inhibitors of Aldo-Keto Reductase AKR1C3","first-page":"5948","volume":"22","author":"Sinreih","year":"2012"},{"key":"10.1016\/j.bioorg.2026.110641_bb0585","first-page":"1286","article-title":"Discovery of novel aldo-keto reductase 1C3 inhibitors as chemotherapeutic potentiators for cancer drug resistance, ACS. Med","volume":"13","author":"He","year":"2022","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0595","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1021\/acs.jmedchem.5c00050","article-title":"Discovery and optimization of a covalent AKR1C3 inhibitor","volume":"68","author":"Grams","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0600","first-page":"1269","article-title":"AI based discovery of a new AKR1C3 inhibitor for anticancer applications, ACS. Med","volume":"15","author":"Pippione","year":"2024","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400081","article-title":"Coumarin-based aldo-keto reductase family 1C (AKR1C) 2 and 3 inhibitors","volume":"19","author":"Jonnalagadda","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110641_bb0610","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.bmcl.2015.09.012","article-title":"Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities","volume":"25","author":"Hendriks","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0615","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bmcl.2011.01.010","article-title":"Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3)","volume":"21","author":"Adeniji","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0620","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0635","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1021\/acs.jmedchem.5c03655","article-title":"Discovery of highly selective AKR1C3 inhibitors to vercome EGFR C797S-mediated osimertinib resistance in non-small cell lung cancer","volume":"69","author":"Guo","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0640","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bmc.2013.12.050","article-title":"Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-\u03b2-hydroxysteroid dehydrogenase (AKR1C3)","volume":"22","author":"Flanagan","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0645","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ejmech.2017.08.046","article-title":"Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach","volume":"139","author":"Pippione","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0650","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ejmech.2018.03.040","article-title":"Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid","volume":"150","author":"Pippione","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114366","article-title":"New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold","volume":"237","author":"Pippione","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116193","article-title":"Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer","volume":"268","author":"Pippione","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0665","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0675","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000519","article-title":"Design, synthesis and cytotoxicity evaluation of novel indole derivatives containing benzoic acid group as potential AKR1C3 inhibitors","volume":"17","author":"Sun","year":"2020","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.110641_bb0680","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1021\/acs.jmedchem.6b00160","article-title":"Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic acid as a potent and selective aldo-keto reductase 1C3 inhibitor","volume":"59","author":"Adeniji","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0685","article-title":"Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3","volume":"7","author":"Pastore","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110641_bb0690","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1021\/acs.jmedchem.3c00213","article-title":"Development of biaryl-containing aldo-keto reductase 1C3 (AKR1C3) inhibitors for reversing AKR1C3-mediated drug resistance in cancer treatment","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0695","doi-asserted-by":"crossref","first-page":"7417","DOI":"10.1021\/jm300841n","article-title":"Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library","volume":"55","author":"Bro\u017ei\u010d","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0700","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00204-018-2258-0","article-title":"Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile","volume":"92","author":"Novotn\u00e1","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0705","first-page":"101","article-title":"Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3, Chem-Biological","volume":"302","author":"Bukum","year":"2019","journal-title":"Interactions"},{"key":"10.1016\/j.bioorg.2026.110641_bb0710","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cbi.2015.09.006","article-title":"In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis","volume":"240","author":"Zhao","year":"2015","journal-title":"Chemico-Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110641_bb0715","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1016\/j.bmcl.2012.03.085","article-title":"Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer","volume":"22","author":"Chen","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.01.001","article-title":"A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics","volume":"192","author":"Wangtrakuldee","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0725","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1158\/1078-0432.CCR-13-1151","article-title":"Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth","volume":"19","author":"Yepuru","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0730","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/cancers12082092","article-title":"Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer","volume":"12","author":"Kafka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110641_bb0740","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bcp.2007.06.014","article-title":"Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia","volume":"74","author":"Guise","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0745","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","article-title":"The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3","volume":"70","author":"Guise","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0760","first-page":"3645","article-title":"A novel selective AKR1C3-activated prodrug AST-3424\/OBI-3424 exhibits broad anti-tumor activity","volume":"11","author":"Meng","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110641_bb0765","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2024.42.16_suppl.3121","article-title":"Safety, tolerability, pharmacokinetics and clinical activity of AST-3424, an AKR1C3-activated bis-alkylating moiety prodrug, in subjects with advanced solid tumors in China: a phase I dose-escalation study","volume":"42","author":"Shukui Qin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0770","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41416-023-02280-4","article-title":"Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors","volume":"129","author":"Tsimberidou","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0780","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cpt.3010","article-title":"Quantitative systems toxicology identifies independent mechanisms for hepatotoxicity and bilirubin elevations due to AKR1C3 inhibitor BAY1128688","volume":"114","author":"Battista","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0785","first-page":"608","article-title":"Suppressed expression of type 2 3alpha\/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma","volume":"3","author":"Zakharov","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0790","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bcp.2016.03.025","article-title":"Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases","volume":"109","author":"Mal\u00e1tkov\u00e1","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0795","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.dmpk.2020.08.004","article-title":"Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase\/reductase isoforms in human livers","volume":"35","author":"Amai","year":"2020","journal-title":"Drug. Metab. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2026.110641_bb0800","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110641_bb0805","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bjc.2016.363","article-title":"Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer","volume":"115","author":"MacLeod","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0810","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1685379","article-title":"KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer","volume":"15","author":"Bambach","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2023.06.1187","article-title":"Radiotherapy resistance in prostate cancer cells: AKR1C3 inhibition of ubiquitinated degradation of Nrf2 through interaction with KEAP1","volume":"117","author":"Lyu","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bioorg.2026.110641_bb0820","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/ph15020185","article-title":"Interrogation of the structure-activity relationship of a lipophilic nitroaromatic prodrug series designed for cancer gene therapy applications","volume":"15","author":"Ashoorzadeh","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110641_bb0825","first-page":"1517","article-title":"Design and biological evaluation of piperazine-bearing nitrobenzamide hypoxia\/GDEPT prodrugs: the discovery of CP-506, ACS. Med","volume":"14","author":"Ashoorzadeh","year":"2023","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110641_bb0830","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-011-1671-3","article-title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","volume":"68","author":"Abou-Alfa","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110641_bb0835","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.2147\/IJN.S241324","article-title":"A aansonone derivative coupled with monoclonal antibody 4D5-modified chitosan inhibit AKR1C3 to treat castration-resistant prostate cancer","volume":"15","author":"Zhou","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioorg.2026.110641_bb0840","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-18-1322","article-title":"AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer.Ther."},{"key":"10.1016\/j.bioorg.2026.110641_bb0845","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42004-024-01177-4","article-title":"Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader","volume":"7","author":"Carmona","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bioorg.2026.110641_bb0850","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110641_bb0855","article-title":"Targeted protein degradation bypassing cereblon and von Hippel-Lindau","volume":"4","author":"Lu","year":"2023","journal-title":"Innovation (Camb)."},{"key":"10.1016\/j.bioorg.2026.110641_bb0860","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/acs.jpcb.5c07053","article-title":"Ternary complex geometry and lysine positioning guide the generation of PROTAC-induced degradable complexes","volume":"130","author":"Kumar","year":"2026","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bioorg.2026.110641_bb0865","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110641_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2025.115580","article-title":"Exploring the roles of AKR1C1, AKR1C2, and AKR1C3 in the nervous system: Mechanisms and perspectives","volume":"397","author":"Chen","year":"2026","journal-title":"Exp. Neurol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:00:33Z","timestamp":1792828833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":174,"alternative-id":["S0045206826011776"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110641","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting selective aldo-keto reductase 1C3 inhibitors and beyond: recent advances and future directions in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110641"}}